背景:了解牛皮癣疾病利用见解治疗(UPLIFT)调查研究于2020年在全球范围内进行,以了解疾病的看法,包括疾病的严重程度,治疗目标,和生活质量(QoL),最近进化了,尤其是轻中度银屑病。这里,介绍了基于美国受访者的UPLIFT调查的主要结果。利用UPLIFT调查的结果可以导致患者和医生之间更有效的互动和更高的患者满意度。
方法:UPLIFT是一项针对皮肤科医生的跨国网络调查,风湿病学家,以及自2020年3月2日至2020年6月3日进行的医疗服务机构诊断为银屑病(PsO)和/或银屑病关节炎(PsA)的患者.
结果:美国受访者包括1006名患者(占全球人口的26.4%;仅PsO,n=535;仅限PsA,n=72;PsO和PsA,n=399)和216名医生(皮肤科医生,n=115;风湿病学家,n=101)。大多数患者(66.4%)报告体表面积(BSA;通过手掌数量评估)≤3;其中,56.2%的人将其疾病评为中度或重度。大多数PsO患者认为他们在治疗目标方面与皮肤科医生有一定程度(40.1%)或非常(49.3%)的一致性。或者,大多数PsA患者认为他们与风湿病学家的关系不太密切(32.1%)或根本不一致(59.3%).大多数患者报告要么中度(PsO,35.5%;PSA,31.8%)或强(PsO,47.7%;PSA,53.9%)需要更好的治疗。在BSA亚组中,大多数患者(60.8%~86.1%)的皮肤病学生活质量指数评分≥6分,表明QoL至少受到中度影响.
结论:尽管有更多的治疗选择,银屑病疾病的管理仍然不理想,许多患者报告中度至重度疾病和QoL受损,即使皮肤受累有限。结果进一步表明,在美国,患者和医生之间的匹配需求尚未满足,以优化PsO和PsA的管理。
了解牛皮癣疾病利用见解治疗(UPLIFT)调查是2020年进行的一项在线调查。参与者是自我报告医疗保健提供者诊断为银屑病和/或银屑病关节炎的患者,皮肤科医生,和风湿病学家。这项调查在北美的几个国家分发,欧洲,和日本共有3806名患者回答了调查。这里介绍了美国患者和医生的结果。UPLIFT旨在了解患者和医生对银屑病和银屑病关节炎的当前看法,尤其是轻度至中度疾病。参与者接受了关于治疗的调查,疾病的严重程度,对生活质量的影响,治疗目标,和病人-医生的互动。在美国,1006名患者和216名医生完成了调查,并被纳入分析。大多数患者的皮肤受累有限,但仍将其疾病评为中度或重度。无论患者是否有少量或大量的皮肤受累,大多数人报告至少对生活质量有中等影响。调查结果表明,患者和医生在治疗目标方面存在脱节,治疗满意度,疾病严重程度,以及他们对医生就诊期间发生的事情的回忆。尽管近年来有新的治疗选择,UPLIFT调查结果显示,患有银屑病和银屑病关节炎的美国患者仍然承受着巨大的疾病负担,并且可以从更好地与医生沟通以优化治疗方案中获益.
BACKGROUND: The Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey study was conducted globally in 2020 to understand how disease perceptions, including disease severity, treatment goals, and quality of life (QoL), have evolved recently, especially for mild-to-moderate psoriatic disease. Here, key findings from the UPLIFT survey based on respondents located in the US are presented. Leveraging results from the UPLIFT survey could lead to more effective interactions between patients and physicians and greater patient satisfaction.
METHODS: UPLIFT was a multinational web-based survey of dermatologists, rheumatologists, and patients who self-reported a healthcare provider diagnosis of psoriasis (PsO) and/or psoriatic arthritis (PsA) conducted from March 2, 2020, to June 3, 2020.
RESULTS: US respondents included 1006 patients (26.4% of global population; PsO only, n = 535; PsA only, n = 72; PsO and PsA, n = 399) and 216 physicians (dermatologists, n = 115; rheumatologists, n = 101). Most patients (66.4%) reported a body surface area (BSA; assessed by number of palms) of ≤ 3; of these, 56.2% rated their disease as moderate or severe. Most patients with PsO felt they were somewhat (40.1%) or very (49.3%) closely aligned with their dermatologists regarding treatment goals. Alternately, most patients with PsA felt that they were not too closely (32.1%) or not at all (59.3%) aligned with their rheumatologists. Most patients reported either a moderate (PsO, 35.5%; PsA, 31.8%) or strong (PsO, 47.7%; PsA, 53.9%) need for better treatments. Across BSA subgroups, most patients (60.8% to 86.1%) had a Dermatology Life Quality Index score ≥ 6, indicating at least a moderately impacted QoL.
CONCLUSIONS: Despite more treatment options, management of psoriatic disease remains suboptimal, with many patients reporting moderate-to-severe disease and impaired QoL, even with limited skin involvement. Results further suggest an unmet need for alignment between patients and physicians in the US to optimize the management of PsO and PsA.
The Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey was an online survey conducted in 2020. The participants were patients who self-reported a healthcare provider diagnosis of psoriasis and/or psoriatic arthritis, dermatologists, and rheumatologists. The survey was distributed in several countries in North America, Europe, and Japan and a total of 3806 patients responded to the survey. Results from US patients and physicians are presented here.UPLIFT was designed to understand current perceptions of patients and physicians relating to psoriasis and psoriatic arthritis, especially for mild-to-moderate disease. Participants were surveyed regarding treatments, severity of disease, impact on quality of life, treatment goals, and patient-physician interactions.In the US, 1006 patients and 216 physicians completed the survey and were included in the analysis. Most patients had limited skin involvement but still rated their disease as moderate or severe. Regardless of whether patients had a small or large amount of skin involved, most reported at least a moderately impacted quality of life. The survey results suggested that there was disconnect between patients and physicians regarding treatment goals, treatment satisfaction, disease severity, and their recollection of what occurred during physician office visits. Despite new treatment options in recent years, the UPLIFT survey results show that US patients with psoriasis and psoriatic arthritis still experience a great disease burden and could benefit from better communication with physicians to optimize their treatment.